Incyte Corp.

INCY

$83.96

-13.7% (1 year change)

Avg closing price

Price range

Market Cap

$18.3 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$75.52 - $110.37

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

38.21x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $18.3 Billion
Enterprise Value $16.4 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return -13.7%
52-Week High $110.37
52-Week Low $75.52
Beta 1.0
Outstanding Shares 220 Million
Avg 30 Day Volume 1.17 Million

Valuation

P/E Ratio 38.21
PEG -35.57
Earnings per Share $2.18
Price to Sales Ratio 7.0
Price to Book Ratio 7.0
Revenue to Enterprise Value 6.05
EBIT to Enterprise Value 28.56
Total Debt to Enterprise Value 0.0
Debt to Equity 0.01

Profitability

Revenue $2.7 Billion
Gross Profit $2.57 Billion
EBIT $573 Million
Net Income $478 Million
Profit Margin 17.7%
Quarterly Earnings Growth (YoY) -107.4%
Return on Equity 17.54%
Return on Assets 13.07%
Return on Invested Capital 18.85%

News

Incyte (NASDAQ:INCY) Releases Quarterly Earnings Results

Incyte (NASDAQ:INCY) Releases Quarterly Earnings Results

Incyte (NASDAQ:INCY) posted its quarterly earnings results on Monday. The biopharmaceutical company reported $0.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $...

Transcript Daily Transcript Daily, 4 months ago
Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs

Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs

Business Wire Business Wire, 4 months ago
Mizuho Securities Stick to Their Hold Rating for Incyte Corp By Investing.com

Mizuho Securities Stick to Their Hold Rating for Incyte Corp By Investing.com

Mizuho Securities Stick to Their Hold Rating for Incyte Corp

Investing.com Investing.com, 5 months ago